semaglutide news today october 2025 Novo Nordisk to present new data in oral 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® Ozempic's entry could reshape diabetes

Look out for these symptoms: Persistent feelings of sadness or hopelessness Loss of interest in activities once enjoyed Changes in appetite or sleep patterns Fatigue or loss of energy Difficulty concentrating or making decisions If you notice any of these signs, talk to your doctor right away

The test reveals predispositions in GLP-1 receptor sensitivity and metabolic factors, but does not predict exact medication response or guarantee specific symptom profiles

Some people lose muscle during GLP-1 treatment because appetite drops, total food intake decreases, and protein intake may become too low

Diabetes Negatively Affects Cortical and Striatal GABAergic Neurons: An Effect That is Partially Counteracted by Exendin-4

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a natural gut hormone released after eating